Sales & Marketing News | pharmaphorum

News

US vulnerable to China's API dominance, says report

China has such a dominant position in pharmaceutical ingredient production that there is a risk it will weaponise access, says a Congressional report.

News

Novo Nordisk cuts Wegovy price ahead of TrumpRx launch

Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide.

News

Sandoz launches first biosimilar Tysabri in US

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

News

Sanofi's type 1 diabetes drug poised for EU rollout

Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes.

News

Lundbeck makes bid for Avadel, trying to displace Alkermes

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.

News

Kura Oncology and Kyowa Kirin logos with Komzifti pill bottle

Kura scores FDA okay for rival to Syndax's leukaemia drug

Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj.

US vulnerable to China's API dominance, says report

Novo Nordisk cuts Wegovy price ahead of TrumpRx launch

Sandoz launches first biosimilar Tysabri in US

Sanofi's type 1 diabetes drug poised for EU rollout

Lundbeck makes bid for Avadel, trying to displace Alkermes

Kura scores FDA okay for rival to Syndax's leukaemia drug

Lilly UK recruits ex-England cricketer as obesity champion

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks